Edition:
United States

SymBio Pharmaceuticals Ltd (4582.T)

4582.T on Tokyo Stock Exchange

218JPY
24 Mar 2017
Change (% chg)

¥-3 (-1.36%)
Prev Close
¥221
Open
¥220
Day's High
¥221
Day's Low
¥218
Volume
444,300
Avg. Vol
676,572
52-wk High
¥564
52-wk Low
¥197

Latest Key Developments (Source: Significant Developments)

SymBio Pharmaceuticals says approval in Japan of anti-cancer drug TREAKISYM® intravenous infusion 25 mg
Wednesday, 28 Sep 2016 02:30am EDT 

SymBio Pharmaceuticals Ltd <4582.T>:Says TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product of the anti-cancer drug TREAKISYM® is approved for manufacturing and marketing in Japan.  Full Article

SymBio Pharmaceuticals says initiation of phase 3 clinical trial on SyB P-1501
Monday, 13 Jun 2016 02:35am EDT 

SymBio Pharmaceuticals Ltd <4582.T> :Announces the Phase 3 clinical trial on “SyB P-1501” – a drug for patient-controlled short-term management of acute postoperative pain during hospitalization, was initiated in Japan.  Full Article

SymBio Pharmaceuticals announces shareholding structure change
Thursday, 19 May 2016 05:06am EDT 

SymBio Pharmaceuticals Ltd <4582.T> : Says a Tokyo-based investment business limited partnership ups stake to 11.56 percent from 0 percent and becomes the top shareholder of the company .Says change occurs on May 11.  Full Article

SymBio announces incorporation of its U.S. subsidiary
Tuesday, 10 May 2016 09:10pm EDT 

SymBio Pharmaceuticals Ltd <4582.T>: Says the company has incorporated its wholly-owned subsidiary in U.S.- SymBio Pharma USA, Inc. on May 11 .Says SymBio Pharma USA, Inc. is engaged in research and development, manufacturing and sales of pharmaceutical products.  Full Article

Symbio Pharmaceuticals issues third series unsecured convertible bonds with warrants via private placement
Thursday, 21 Apr 2016 08:15pm EDT 

Symbio Pharmaceuticals Ltd:Issues the third series unsecured convertible bonds with warrants via private placement and raises 3 billion yen on April 22.  Full Article

Symbio Pharmaceuticals to issue third series unsecured convertible bonds with warrants through private placement
Wednesday, 6 Apr 2016 03:00am EDT 

Symbio Pharmaceuticals Ltd:To issue the third series unsecured convertible bonds with warrants through private placement to Japan-based investment limited liability partnership.To raise 3 billion yen.Says payment date April 22.Conversion price of 211 yen.Proceeds raised will be used for research and development.  Full Article

Symbio Pharmaceuticals and Teikyo Heisei University enter into a Joint Research and Development Agreement
Sunday, 7 Feb 2016 06:00pm EST 

Symbio Pharmaceuticals Ltd:Says the co and Teikyo Heisei University enters into an agreement on Feb. 8 with Teikyo Heisei University to collaborate on the research and development of an innovative anti-cancer drug which uses the TTR1 nano-agonist molecule.  Full Article

Symbio Pharmaceuticals starts Global Phase 3 Trial for IV Rigosertib
Sunday, 27 Dec 2015 06:00pm EST 

Symbio Pharmaceuticals Ltd:Says it has started the global Phase 3 trial in Japan for the IV formulation of rigosertib to treat relapsed or refractory higher-risk myelodysplastic syndromes (HR-MDS) patients.While SymBio will conduct the INSPIRE trial in Japan, SymBio’s U.S. partner, Onconova Therapeutics, Inc will conduct the INSPIRE trial in the U.S and Europe.  Full Article

Symbio Pharmaceuticals Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
Sunday, 6 Dec 2015 07:00pm EST 

Symbio Pharmaceuticals Ltd:Announces the start of the Phase I clinical trial in Japan for oral rigosertib combined with azacytidine (Vidaza: currently marketed by Nippon Shinyaku Co., Ltd.) in higher-risk myelodysplastic syndrome (MDS) patients (“Phase I Combination Trial”).SymBio has completed its Phase I clinical trial in Japan for oral rigosertib as a mono therapy in transfusion-dependent lower-risk MDS patients on June 26.And upon completion of this Phase I Combination Trial, SymBio will consider participating in a global Phase III trial which its US partner, Onconova Therapeutics, Inc. plans to initiate.According to Onconova, the Phase II trial enrollment is complete and the company plans to present these study results at the 57th ASH Meeting currently held from Dec. 5 to Dec. 8.  Full Article

Symbio Pharmaceuticals announces completion of rigosertib phase I trial
Friday, 30 Oct 2015 01:45am EDT 

Symbio Pharmaceuticals Ltd:Announces completion of anticancer drug rigosertib phase I trial in patients with Myelodysplastic syndromes (MDS).To take part in phase III joint trial by Onconova Therapeutics Inc.  Full Article

More From Around the Web

BRIEF-SymBio Pharmaceuticals says approval in Japan of anti-cancer drug TREAKISYM intravenous infusion 25 mg

* Says TREAKISYM Intravenous Infusion 25 mg, a standard low-dose product of the anti-cancer drug TREAKISYM is approved for manufacturing and marketing in Japan